Tags: Pfizer | Profits | Earnings | Drugs

Pfizer Beats Forecasts as Oncology Drugs Grow

Tuesday, 29 Jul 2014 07:56 AM

Pfizer Inc., which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.

The largest U.S. drugmaker on Tuesday said it had earned $2.91 billion, or 45 cents per share. That compared with $14.1 billion, or $1.98 per share, a year earlier, when Pfizer received more than $10 billion in proceeds from the spinoff of its animal health business into a new publicly traded company, Zoetis.

Excluding special items, Pfizer earned 58 cents per share. Analysts on average expected 57 cents, according to Thomson Reuters I/B/E/S.

Sales fell 2 percent to $12.77 billion, hurt by declines for generic medicines that Pfizer calls established products, but they exceeded Wall Street expectations of $12.46 billion.

Pfizer stuck to its prior earnings forecast of $2.20 to $2.30 per share for the full year.

Shares of Pfizer were up 1 percent at $30.41 in trading before the market opened.


© 2017 Thomson/Reuters. All rights reserved.

 
1Like our page
2Share
Companies
Pfizer Inc., which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.
Pfizer, Profits, Earnings, Drugs
159
2014-56-29
Tuesday, 29 Jul 2014 07:56 AM
Newsmax Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved